HOWL News

Are PSNL, MKTX, BZH, HOWL Obtaining Fair Deals for their Shareholders? Are PSNL, MKTX, BZH, HOWL Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, Sept. 4, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed...

Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Werewolf Therapeutics, Inc. (NASDAQ: HOWL) and Ambros Therapeutics, Inc. Upon closing of the proposed transaction, Werewolf shareholders are expected to own approximately 6.8% of the combined company.Halper Sadeh...

$HAREHOLDER ALERT: The M&A Class Action Firm Announce the Investigation of the Merger - HOWL, HZO, TYFG and FULC $HAREHOLDER ALERT: The M&A Class Action Firm Announce the Investigation of the Merger - HOWL, HZO, TYFG and FULC PR Newswire NEW YORK, Aug. 23, 2026 NEW YORK, Aug. 23, 2026 /PRNewswire...

Gainers Werewolf Therapeutics (NASDAQ:HOWL) shares increased by 108.1% to $0.9 during Friday's regular session. The market value of their outstanding shares is at $20.9 million. Jupiter Neurosciences (NASDAQ:JUNS)read more...

Dow gains 400 points, Materials sector up 2.3%, Werewolf Therapeutics up 113%, S&P PMI rises to strongest level since April 2022.read more...

Biotech mergers can completely remake small public companies overnight, particularly when a transaction brings together a late-stage clinical asset, institutional capital and a clear regulatory path. Add an orphan disease with no FDA-approved drug therapy, and investors suddenly have a very different company to value than the one that existed the day before.Shares of Werewolf Therapeutics, Inc. (Nasdaq: HOWL) are soaring Friday after the immuno-oncology company announced a definitive all-stock merger with privately held Ambros Therapeutics alongside an oversubscribed $150 million private ...

Biotech mergers can completely remake small public companies overnight, particularly when a transaction brings together a late-stage clinical asset, institutional capital and a clear regulatory path. Add an orphan disease with no FDA-approved drug therapy, and investors suddenly have a very different company to value than the one that existed the day before.Shares of Werewolf Therapeutics, Inc. (Nasdaq: HOWL) are soaring Friday after the immuno-oncology company announced a definitive all-stock merger with privately held Ambros Therapeutics alongside an oversubscribed $150 million private ...

Werewolf Therapeutics and Ambros Therapeutics merge in an all-stock deal with $150M in financing to advance Phase 3 CRPS-1 candidate.read more...

Werewolf Therapeutics surged after announcing a $500 million merger with Ambros Therapeutics, putting focus on Israel Englander's holding.read more...